Who are Vancomycin and Gentamicin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vancomycin and Tobramycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vancomycin-and-gentamicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Vancomycin and Gentamicin — Competitive Intelligence Brief

Vancomycin and Gentamicin (Vancomycin and Gentamicin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination (glycopeptide + aminoglycoside). Area: Infectious Disease.

marketed Antibiotic combination (glycopeptide + aminoglycoside) Bacterial cell wall (vancomycin) and bacterial 30S ribosome (gentamicin) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Vancomycin and Gentamicin (Vancomycin and Gentamicin) — Memorial Sloan Kettering Cancer Center. Vancomycin and gentamicin are a combination antibiotic regimen that inhibits bacterial cell wall synthesis and protein synthesis to treat serious infections.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vancomycin and Gentamicin TARGET	Vancomycin and Gentamicin	Memorial Sloan Kettering Cancer Center	marketed	Antibiotic combination (glycopeptide + aminoglycoside)	Bacterial cell wall (vancomycin) and bacterial 30S ribosome (gentamicin)
Vancomycin and Tobramycin	Vancomycin and Tobramycin	Major Extremity Trauma Research Consortium	phase 3	Antibiotic combination (glycopeptide + aminoglycoside)	Bacterial cell wall (vancomycin) and 30S ribosomal subunit (tobramycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination (glycopeptide + aminoglycoside) class)

Major Extremity Trauma Research Consortium · 1 drug in this class
Memorial Sloan Kettering Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vancomycin and Gentamicin — Competitive Intelligence Brief. https://druglandscape.com/ci/vancomycin-and-gentamicin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab